M. Debily

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Marie Anne Debily, M Debily, M.-a. Debily, Marie‐anne Debily, M-a Debily, Marie-anne Debily
Publication record
79 papers · 3,803 citations · H-index 23

PAPERS

P10.21.B DIFFUSE MIDLINE GLIOMA, H3 K27 AND BRAF/FGFR1 CO-ALTERED: DISTINCT BIOLOGY AND THERAPEUTIC OPPORTUNITIES
20250 citationsauthor #25
CTP-11. Biological Medicines for Diffuse Intrinsic Pontine Gliomas (DIPG) Eradication (BIOMEDE). An International Randomized Phase II Biomarker-driven Platform Trial Comparing Three Targeted Therapies in Combination with Radiotherapy
20250 citationsauthor #1
Abstract 155: Clinico-radiological and histomolecular analyses identify of a new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered
20240 citationsauthor #20
PATH-37. A NEW SUBTYPE OF DIFFUSE MIDLINE GLIOMA, H3 K27 AND BRAF/FGFR1 CO-ALTERED, EXHIBITS SPECIFIC BIOLOGICAL CHARACTERISTICS AND NEW THERAPEUTIC VULNERABILITIES
20240 citationsauthor #25
Abstract 154: Diffuse midline glioma invasion and metastasis rely on cell-autonomous signaling through a phenotypic switch controlled by BMP7
20240 citationsauthor #24
Glioma oncogenesis in the Constitutional mismatch repair deficiency (CMMRD) syndrome
20243 citationsauthor #20
VRK3 depletion induces cell cycle arrest and metabolic reprogramming of Pontine Diffuse Midline Glioma (DMG)-K27 altered cells
20230 citationsauthor #15
HGG-15. HIGH-GRADE GLIOMAS OCCURRING IN TEENAGERS AND YOUNG ADULT PATIENTS COMPRISE NOVEL MOLECULAR SUBGROUPS
20230 citationsauthor #49
VRK3 depletion induces cell cycle arrest and metabolic reprogramming of pontine diffuse midline glioma - H3K27 altered cells
20231 citationsauthor #16
Biological medicines for diffuse intrinsic pontine glioma (DIPG) eradication (BIOMEDE): Final results of an international randomized phase II platform trial comparing 3 targeted therapies in combination with radiotherapy from ITCC, SIOPE-Brain and ANZCHOG.
20235 citationsauthor #10
DIPG-43. CLINICAL AND MOLECULAR CHARACTERISTIC OF A NEW SUBTYPE OF DMG, H3K27-ALTERED WITH MAPK-ACTIVATING CO-DRIVER MUTATIONS
20230 citationsauthor #15
DIPG-38. PATIENT-DERIVED THREE-DIMENSIONAL AVATARS REVEAL CELL-AUTONOMOUS MECHANISMS DRIVING INVASION AND METASTATIC PROGRESSION IN DIFFUSE MIDLINE GLIOMAS
20230 citationsauthor #21
Pediatric high-grade glioma MYCN is frequently associated with Li-Fraumeni syndrome
202311 citationsauthor #13
Diffuse midline glioma invasion and metastasis rely on cell-autonomous signaling
202314 citationsauthor #24
HGG-17. SINGLE-CELL AND SPATIAL ANALYSES DECIPHER THE UNIQUE INVASIVE GROWTH PATTERN OF GLIOMATOSIS CEREBRI
20230 citationsauthor #20
A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation
202332 citationsauthor #20
NF2 and ZFTA evaluation in the diagnostic algorithm of pediatric posterior fossa ependymoma with H3K27ME3 retained expression
20231 citationsauthor #3
The dural angioleiomyoma harbors frequent GJA4 mutation and a distinct DNA methylation profile
20221 citationsauthor #22
The dural angioleiomyoma harbors frequent GJA4 mutation and a distinct DNA methylation profile
20229 citationsauthor #22
The genomic landscape of dysembryoplastic neuroepithelial tumours and a comprehensive analysis of recurrent cases
20228 citationsauthor #2
HGG-41. Glioma oncogenesis in the constitutional mismatch repair deficiency (CMMRD) syndrome
20220 citationsauthor #20
Pediatric spinal pilocytic astrocytomas form a distinct epigenetic subclass from pilocytic astrocytomas of other locations and diffuse leptomeningeal glioneuronal tumours
202213 citationsauthor #26
Copy-number alterations reshape the classification of diffuse intrinsic pontine gliomas. First exome sequencing results of the BIOMEDE trial.
20214 citationsauthor #24
EPCO-03. GLIOMA ONCOGENESIS IN THE CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY (CMMRD) SYNDROME
20210 citationsauthor #20
Radiogenomics of diffuse intrinsic pontine gliomas (DIPGs): correlation of histological and biological characteristics with multimodal MRI features
202119 citationsauthor #6
Deciphering the genetic and epigenetic landscape of pediatric bithalamic tumors
20217 citationsauthor #2
The pediatric supratentorial MYCN-amplified high-grade gliomas methylation class presents the same radiological, histopathological and molecular features as their pontine counterparts
202035 citationsauthor #2
DIPG-58. HISTONE H3 WILD-TYPE DIPG/DMG OVEREXPRESSING EZHIP EXTEND THE SPECTRUM OF DIFFUSE MIDLINE GLIOMAS WITH PRC2 INHIBITION BEYOND H3-K27M MUTATION
20200 citationsauthor #17
Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation
2020135 citationsauthor #17
DIPG-35. BIOLOGICAL MEDICINE FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) ERADICATION: RESULTS OF THE THREE ARM BIOMARKER-DRIVEN RANDOMIZED BIOMEDE 1.0 TRIAL
20207 citationsauthor #12
A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR.
2020110 citationsauthor #15
DIPG-56. EXPLORATION OF TUMOR/STROMA INTERACTIONS IN DIPG XENOGRAFT BY SPECIES-SPECIFIC RNA-SEQ DECONVOLUTION INDICATES A ROLE OF MICROGLIA CELL IN DIPG DEVELOPMENT
20200 citationsauthor #11
The pediatric supratentorial MYCN-amplified high-grade gliomas methylation class presents the same radiological, histopathological and molecular features as their pontine counterparts
20200 citationsauthor #2
High-grade gliomas in adolescents and young adults highlight histomolecular differences with their adult and paediatric counterparts.
202047 citationsauthor #5
EZHIP is a specific diagnostic biomarker for posterior fossa ependymomas, group PFA and diffuse midline gliomas H3-WT with EZHIP overexpression
20200 citationsauthor #3
DIPG-61. RESCUE REGIMENS AFTER BIOMEDE: POSSIBLE INFLUENCE ON OS ASSESSMENT
20200 citationsauthor #10
EZHIP is a specific diagnostic biomarker for posterior fossa ependymomas, group PFA and diffuse midline gliomas H3-WT with EZHIP overexpression
202037 citationsauthor #3
DIPG-10. TP53 PATHWAY ALTERATION IS DRIVING RADIORESISTANCE IN DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPG)
20190 citationsauthor #14
The dark matter of diffuse intrinsic pontine gliomas: an update
20191 citationsauthor #2
PDCT-01. BIOLOGICAL MEDICINE FOR DIFFUSE INTRINSIC PONTINE GLIOMAS ERADICATION (BIOMEDE): RESULTS OF THE THREE-ARM BIOMARKER-DRIVEN RANDOMIZED TRIAL IN THE FIRST 230 PATIENTS FROM EUROPE AND AUSTRALIA
20194 citationsauthor #12
PDTM-36. WHOLE EXOME SEQUENCING (WES) OF DIPG PATIENTS FROM THE BIOMEDE TRIAL REVEALS NEW PROGNOSTIC SUBGROUPS WITH SPECIFIC ONCOGENIC PROGRAMMES
20191 citationsauthor #1
An integrative radiological, histopathological and molecular analysis of pediatric pontine histone-wildtype glioma with MYCN amplification (HGG-MYCN)
201930 citationsauthor #2
TP53 Pathway Alterations Drive Radioresistance in Diffuse Intrinsic Pontine Gliomas (DIPG)
201983 citationsauthor #16
A kinome-wide shRNA screen uncovers vaccinia-related kinase 3 (VRK3) as an essential gene for diffuse intrinsic pontine glioma survival
201913 citationsauthor #12
LGG-04. CLINICO-HISTO-MOLECULAR LANDSCAPE OF EIGHTY-TWO PEDIATRIC AND YOUNG ADULT DYSEMBRYOPLASTIC NEUROEPITHELIAL TUMORS
20190 citationsauthor #5
Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging
201864 citationsauthor #8
DIPG-26. MOLECULAR DETERMINANTS OF RESPONSE TO RADIOTHERAPY IN DIPG: A CLINICAL AND IN VITRO STUDY
20180 citationsauthor #6
HGG-42. GLIOMA ONCOGENESIS IN CONSTITUTIONNAL MISMATCH REPAIR DEFICIENCY (CMMRD) SYNDROME: A CLINICO-PATHOLOGICAL AND MOLECULAR STUDY IN 15 PATIENTS
20181 citationsauthor #3
Diffuse intrinsic pontine gliomas (DIPG) at recurrence: is there a window to test new therapies in some patients?
201825 citationsauthor #5
DIPG-25. A KINOME-WIDE shRNA SCREEN UNCOVERS VRK3 AS AN ESSENTIAL GENE FOR DIPG SURVIVAL
20180 citationsauthor #8
Cerebral blood flow changes after radiation therapy identifies pseudoprogression in diffuse intrinsic pontine gliomas
201823 citationsauthor #10
DIPG-20. PRE-RANDOMISATION CENTRAL REVIEW AND REAL-TIME BIOMARKERS SCREENING IN THE MULTICENTRE BIOLOGICAL MEDICINE FOR DIPG ERADICATION (BIOMEDE) TRIAL: LESSONS LEARNT FROM THE FIRST 120 BIOPSIES
20183 citationsauthor #2
Transcriptomic and epigenetic profiling of ‘diffuse midline gliomas, H3 K27M-mutant’ discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location
2018100 citationsauthor #15
DIPG-21. GENOMIC LANDSCAPE OF THE FIRST 100 TUMORS REGISTERED IN THE BIOLOGICAL MEDICINE FOR DIPG ERADICATION (BIOMEDE) TRIAL
20171 citationsauthor #14
New in vivo avatars of diffuse intrinsic pontine gliomas (DIPG) from stereotactic biopsies performed at diagnosis
201722 citationsauthor #14
Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma
2017875 citationsauthor #50
Cancer Cell Integrated molecular meta-analysis of 1000 paediatric high grade and diffuse intrinsic pontine glioma
20170 citationsauthor #51
New in vivo avatars of diffuse intrinsic pontine gliomas (DIPG) from stereotactic biopsies performed at diagnosis.
201725 citationsauthor #14
HG-55DEVELOPMENT OF IN VIVO MODELS OF DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) FROM STEREOTACTIC BIOPSIES PERFORMED AT DIAGNOSIS
20160 citationsauthor #9
Histone H3 genotyping refines clinico-radiological diagnostic and prognostic criteria in DIPG
201611 citationsauthor #3
Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes
2015524 citationsauthor #19
Functionally-defined Therapeutic Targets in Diffuse Intrinsic Pontine Glioma
2015560 citationsauthor #6
Erratum: Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
201581 citationsauthor #6
BT-02FUNCTIONALLY-DEFINED THERAPEUTIC TARGETS IN DIFFUSE INTRINSIC PONTINE GLIOMA.
20152 citationsauthor #6
HIGH GRADE GLIOMAS AND DIPG
20140 citationsauthor #198
Learning a Markov Logic network for supervised gene regulatory network inference
201317 citationsauthor #5
A Synthetic Interaction Screen Identifies Factors Selectively Required for Proliferation and TERT Transcription in p53-Deficient Human Cancer Cells
201237 citationsauthor #5
Markov Logic Network for supervised gene regulation inference: application to the ID2 regulatory network in human keratinocytes
20121 citationsauthor #5
Large Scale RNAi Screen Reveals That the Inhibitor of DNA Binding 2 (ID2) Protein Is Repressed by p53 Family Member p63 and Functions in Human Keratinocyte Differentiation*
201113 citationsauthor #3
A Functional and Regulatory Network Associated with PIP Expression in Human Breast Cancer
200940 citationsauthor #1
Cell microarray for functional exploration of genomes.
20078 citationsauthor #2
The H-Invitational Database (H-InvDB), a comprehensive annotation resource for human genes and transcripts
200766 citationsauthor #82
Cell microarrays in drug discovery.
200698 citationsauthor #3
The Human Anatomic Gene Expression Library (H-ANGEL), the H-Inv integrative display of human gene expression across disparate technologies and platforms
200420 citationsauthor #2
Integrative Annotation of 21,037 Human Genes Validated by Full-Length cDNA Clones
2004350 citationsauthor #50
Correction: Integrative Annotation of 21,037 Human Genes Validated by Full-Length cDNA Clones
20042 citationsauthor #50
Expression and molecular characterization of alternative transcripts of the ARHGEF5/TIM oncogene specific for human breast cancer.
200346 citationsauthor #1
Intragenic amplification and formation of extrachromosomal small circular DNA molecules from the PIP gene on chromosome 7 in primary breast carcinomas
200221 citationsauthor #4
Initiation of the breakage-fusion-bridge mechanism through common fragile site activation in human breast cancer cells: the model of PIP gene duplication from a break at FRA7I.
2002142 citationsauthor #2

TIMELINE

2002 163 citations

2003 46 citations

2004 372 citations

2006 98 citations

2007 74 citations

2009 40 citations

2011 13 citations

2012 38 citations

2013 17 citations

2014 0 citations

2015 1,167 citations

2016 11 citations

2017 923 citations

2018 216 citations

2019 132 citations

2020 371 citations

2021 30 citations

2022 31 citations

2023 64 citations

2024 3 citations

2025 0 citations

M. Debily

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT